Strategy
MSTR
Meta Platforms
META
Oracle
ORCL
Amazon
AMZN
Salesforce
CRM
US Stock MarketDetailed Quotes
LGVN Longeveron
- 1.510
- +0.030+2.03%
Close Feb 26 16:00 ET
22.40MMarket Cap-0.27P/E (TTM)
1.525High1.460Low65.17KVolume1.480Open1.480Pre Close97.80KTurnover0.56%Turnover RatioLossP/E (Static)14.84MShares6.40052wk High0.87P/B17.64MFloat Cap0.77152wk Low--Dividend TTM11.68MShs Float450.000Historical High--Div YieldTTM4.39%Amplitude0.770Historical Low1.500Avg Price1Lot Size
About Longeveron Company
Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.
Company Profile
SymbolLGVN
Company NameLongeveron
Listing DateFeb 12, 2021
Issue Price10.00
Founded2014
CEOMr. Mohamed Wael Ahmed Hashad
MarketNASDAQ
Employees25
Fiscal Year Ends12-31
AddressLife Science & Technology Park,1951 Northwest 7th Avenue,Suite 250
CityMiami
ProvinceFlorida
CountryUnited States of America
Zip Code33136
Phone1-305-909-0840
Websitehttp://www.longeveron.com
Company Executives
- Name
- Position
- Salary
- Mohamed Wael Ahmed Hashad
- Chief Executive Officer and Director
- 1.58M
- Dr. Joshua M. Hare, M.D.
- Chief Science Officer and Chairman of the Board
- 75.31K
- Dr. Nataliya Agafonova
- Chief Medical Officer
- --
- Lisa Locklear
- Treasurer, Chief Financial Officer and Principal Accounting Officer
- 380.78K
- Lisa McClain-Moss
- Vice President, Manufacturing
- --
- Dr. Roger Hajjar
- Director
- --
- Neha Motwani
- Director
- --
- Rock Soffer
- Director
- 43.81K
- Khoso Baluch
- Independent Director
- 35.97K
- Ursula Ungaro
- Independent Director
- 50.81K
- Richard N. Kender, M.B.A.
- Independent Director
- --
- Paul Lehr
- General Counsel and Secretary
- 554.06K
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.